KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Free Cash Flow (2016 - 2025)

Regeneron Pharmaceuticals has reported Free Cash Flow over the past 17 years, most recently at $922.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $922.0 million for Q4 2025, down 13.28% from a year ago — trailing twelve months through Dec 2025 was $4.1 billion (up 11.35% YoY), and the annual figure for FY2025 was $4.1 billion, up 11.35%.
  • Free Cash Flow for Q4 2025 was $922.0 million at Regeneron Pharmaceuticals, down from $1.4 billion in the prior quarter.
  • Over the last five years, Free Cash Flow for REGN hit a ceiling of $3.3 billion in Q3 2021 and a floor of $173.5 million in Q2 2024.
  • Median Free Cash Flow over the past 5 years was $987.4 million (2024), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Free Cash Flow: surged 905.01% in 2021 and later plummeted 85.17% in 2022.
  • Regeneron Pharmaceuticals' Free Cash Flow stood at $2.2 billion in 2021, then decreased by 29.31% to $1.6 billion in 2022, then crashed by 46.53% to $838.3 million in 2023, then grew by 26.83% to $1.1 billion in 2024, then dropped by 13.28% to $922.0 million in 2025.
  • The last three reported values for Free Cash Flow were $922.0 million (Q4 2025), $1.4 billion (Q3 2025), and $925.4 million (Q2 2025) per Business Quant data.